Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

Read full story on Wired
Share
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
AI disclosure

Summary

It will be the first time ER-100 technology they claim can reverse aging in cells has been tested on a human.

Original reporting

Open original source

Related coverage

Read full article on Wired

Get the AFBytes Brief

Major stories, AI-assisted analysis, and what to watch next. Free, monthly, unsubscribe anytime.